Asset
PATIDISTROGENE BEXOPARVOVEC
Sarepta Therapeutics Inc. Common Stock (DE)
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01976091 | phase1_2 | completed | 2015-02-01 | 2019-03-14 | Sarepta Therapeutics, Inc. | A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D) |
| NCT06747273 | phase1 | terminated | 2025-01-09 | 2025-06-18 | Sarepta Therapeutics, Inc. | Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States |
FDA applications (0)
This company has no applications containing this asset.